1300SMILES Limited Overview
1300SMILES Limited is a regional-Queensland-anchored dental services organisation (DSO). It built a 33-practice network concentrated in Queensland's ten largest population centres plus a small New South Wales presence. Its model is service-centric. The company owns the surgeries, equipment and support staff and provides billing, marketing, accreditation and procurement. Self-employed dentists practise inside its facilities under Dental Service Agreements and pay the company a share of their production. For two decades under founder Dr Daryl Holmes, the company was distinctive among ASX dental roll-ups for its conservatism: modest leverage, owner-like capital allocation, uninterrupted fully franked dividends from listing, and a disciplined, opportunistic approach to acquisitions. That record culminated in a FY2021 result of A$65.8m over-the-counter revenue and A$9.6m NPAT. It then sold to BGH Capital and OTPP-backed Abano Healthcare at 13.5x underlying pre-AASB 16 EBITDA. Today it is a regional brand inside one of Australasia's largest dental platforms.
Company's own description (Annual Report FY2021, paraphrased)
1300SMILES described itself as the owner and operator of full-service dental facilities in New South Wales and in Queensland's ten major population centres. It stated an intention to expand into other Australian regions, both by opening its own sites and by acquiring established practices. Corporate and administrative functions sit in Townsville.
The operating model works as follows:
-
The company provides dental surgeries, practice management and related services to self-employed dentists who run their own practices.
-
Those dentists pay fees under a Dental Service Agreement.
-
In some cases the company employs dentists directly.
Services provided to dentists include:
-
Marketing
-
Administration
-
Billing and collections
-
Facility certification and licensing
-
All support staff, equipment and facilities
-
Group-level purchasing of consumables
The dentist base ranges from new graduates to experienced practitioners. Some have special interests in endodontics, oral surgery, implants and periodontics and cross-refer within the network.
The stated growth drivers (Annual Report FY2021) were:
-
Attracting more dentists to existing facilities and expanding those at full capacity.
-
Lifting the turnover of existing dentists through benchmarking, training and mentoring.
-
Greenfield practices in existing and new regions.
-
Acquiring substantial practices on favourable terms.
-
Managing dental facilities owned by others.
Independent characterisation
Business model. 1300SMILES is best understood as a dental infrastructure-and-services landlord with operating leverage, not a clinical provider in the accounting sense. The economic engine is the gap between over-the-counter (OTC) patient billings and what the company retains after dentists take their share.
The company reported both measures. In FY2021:
-
OTC revenue (total patient fees billed through its practices) was A$65.8m.
-
A$20.8m was retained by self-employed dentists.
-
Statutory revenue was therefore A$44.9m.
The implied company retention ratio was about 68% of OTC billings (derived). This is consistent with a model where the company carries the full fixed cost base (staff, premises, equipment, consumables), and the dentist's share is effectively a variable cost.
Revenue model mix (FY2021, Note 5 and Note 6).
-
Services, in the form of DSA service fees: 96.8%
-
Financial and other income: 3.2%
-
Product, subscription and licensing revenue: not material as separate lines
A membership/treatment-plan revenue stream (the "$1-a-day Dental Care Plan") was recognised over time. It was disclosed only within receivables (A$0.2m at 30 June 2021), not as a separate revenue line.
Value chain position. 1300SMILES sits between upstream suppliers and downstream payers:
-
Upstream: dental consumables and equipment suppliers, dental labs, landlords, and the dentist labour market.
-
Downstream: patients and payers, including out-of-pocket patients, private health insurers (the website lists preferred-provider relationships with Medibank, nib, Bupa, HCF, CBHS, Westfund, Defence Health and TUH), and the Commonwealth Child Dental Benefits Schedule (CDBS).
Customer types. The company has two customer classes:
-
Dentists, who are the contractual customers paying service fees.
-
Patients, who are the economic end-users: families, children (CDBS), adults seeking general, restorative and cosmetic care, and regional populations under-served by public dental services.
End-markets. The end-market is Australian private general dental services, with a regional Queensland focus (Townsville, Cairns, Mackay, Rockhampton, Gladstone, Bundaberg, Toowoomba, the Sunshine Coast and Greater Brisbane) and a small Sydney footprint (Cammeray).
Strategy
Stated strategy at delisting
Annual Report FY2021, paraphrased themes:
Core objective: keep growing profits and shareholder returns while giving staff and dentists a rewarding environment.
Organic growth: recruit dentists into under-utilised chairs, expand full-capacity sites, and lift dentist productivity through benchmarking and mentoring.
Greenfields: new practices in existing and new regions.
Acquisitions: opportunistic, on favourable terms only. Management repeatedly stressed it would not buy or keep practices just to inflate site counts (MD letter, February 2020).
Third-party management: managing dental facilities owned by others.
The FY2021 outlook listed three likely developments: ongoing opportunistic acquisitions, continued organic growth of existing practices, and ongoing investigation of greenfield sites.
Initiatives in the final 24 months as a listed company (Sep 2019 – Dec 2021)
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Pursuit of Maven Dental (116 practices) | H2 CY2019 | A transformational bid that would have roughly quadrupled scale. Lost to BGH/OTPP's whole-company bid for Abano | Business News Australia |
| Smiles Inclusive opportunism | December 2019 | Bought two healthy practices from the distressed peer rather than the whole company | Business News Australia |
| CBA facility and accordion | August 2019 | A$50m headroom for an acquisition program | Note 24 |
| COVID-19 cash conservation | March–September 2020 | Practice closures, NED fee waivers, JobKeeper (A$4.0m over FY2020–FY2021) | Annual Report FY2021; Kalkine |
| Central/Western Queensland bolt-ons | December 2020 – August 2021 | Bundaberg Central Point, Chinchilla, fourth Bundaberg practice | Annual Report FY2021 |
| Sale to Abano | August–December 2021 | Strategic exit; brand integrated into the Abano platform | ASX announcements |
Post-acquisition strategy (under Abano)
At announcement, Abano positioned 1300SMILES as a complementary addition to its Australian network of 106 practices (largely Maven Dental). Its CEO cited BGH Capital's and Ontario Teachers' experience in healthcare as support for clinician outcomes and the next phase of growth.
The 1300SMILES website now presents it as an Abano Group brand alongside Maven and Lumino. Abano's careers platform recruits for all brands. Under prior listed ownership, Abano articulated a goal of 10% share of the roughly NZ$11bn trans-Tasman dental market (NBR). Current Abano targets are not publicly disclosed.
Not publicly disclosed: medium-term financial targets, ESG commitments and cost programs specific to 1300SMILES.
Products & Services
All offerings sit within the single reportable segment. Clinical services are delivered by independent (self-employed) or employed dentists operating from 1300SMILES facilities. The company's direct "product" is the practice platform. "Launch year" denotes the first public reference found, not necessarily the true launch date.
Platform services sold to dentists (B2B)
| Offering | Description | Target customer | Pricing model | Source |
|---|---|---|---|---|
| Dental Service Agreement (DSA) | Turnkey surgery access: chairs, equipment, support staff, reception, sterilisation | Self-employed general dentists and specialists | Service fee retained from dentist production (company retained ~68% of OTC in FY2021, derived) | Annual Report FY2021 |
| Practice management and administration | Billing, collections, health-fund claiming, scheduling | DSA dentists | Bundled in DSA | Annual Report FY2021 |
| Marketing | Group brand, 1300 number, digital booking, patient offers | DSA dentists | Bundled | Annual Report FY2021 |
| Accreditation and licensing | QIP practice accreditation; radiation licences (Radiation Safety Act 1999 (Qld), Radiation Control Act 1990 (NSW)); trade waste approvals | DSA dentists | Bundled | SIA "Material Licence" definition |
| Procurement | Group buying of consumables and lab services | DSA dentists | Bundled | Annual Report FY2021 |
| Benchmarking, training, mentoring | Performance coaching to lift dentist turnover | DSA dentists | Bundled | Annual Report FY2021 |
| Practice acquisition / exit pathway | Buys owner-dentists' practices; the vendor typically stays through an earn-out | Retiring or practice-owning dentists | Cash plus contingent earn-out | Annual Report FY2021 (Chinchilla, Bundaberg) |
| Facility management for third parties | Managing dental facilities owned by others (stated growth driver) | Third-party owners | — | Annual Report FY2021 |
| Share-loan incentive program | Company-funded loans for consultants, contractors and executives to buy shares (3.5% interest, escrowed, full recourse) | Key dentists and executives | A$1.65m principal outstanding at June 2021 | Note 14 |
Patient-facing clinical services (B2C, delivered through the network)
| Category | Named services | Notes |
|---|---|---|
| General dentistry | Check-ups, cleans, x-rays, fillings, dentures (incl. immediate dentures), emergency dentistry | Current new-patient offer: check-up, clean and bitewing x-rays for A$249 at participating practices (valid to 15 January 2027) |
| Preventative | Fissure seals, custom mouthguards, bruxism/TMJ management, sleep apnoea oral appliances | Mouthguard promotion tied to Queensland school-sport requirements |
| Restorative | Fillings, root canal therapy, crowns, bridges, implants, dentures | — |
| Cosmetic | Teeth whitening (in-chair and take-home), veneers, composite bonding, smile makeovers | — |
| Orthodontics | Braces, Invisalign®, ClearCorrect aligners, QuickStraightTeeth, Fast Braces, early (interceptive) treatment, adult orthodontics | Third-party aligner brands; not proprietary |
| Children's dentistry | CDBS services | Website states all clinics support CDBS (benefit cap stated as A$1,052) |
| Specialist-interest care | Endodontics, oral surgery, implants, periodontics via internal cross-referral | Annual Report FY2021 |
Sources: company website (October 2026) and blogs.
Patient financing and membership products
| Product | Description | Launch / first reference | Pricing | Source |
|---|---|---|---|---|
| $1-a-day Dental Care Plan | Membership plan bundling preventive care | Referenced FY2014–FY2015 | About A$1 per day | Press releases, February 2014 and August 2015 |
| 1300SMILES DMA Vouchers | In-house financing for higher-value treatment | ~FY2015 | From A$99 per week | Press release, 18 August 2015 |
| "Drill now, pay later" financing | Deferred-payment options | Referenced in AFR coverage | — | AFR company page |
| Third-party BNPL | HUMM, ZIP Health, Afterpay | Current | Provider terms | Website, 2026 |
| Membership discounts and offers | Current membership/discount scheme | Current | — | Website, 2026 |
| Health-fund preferred provider | Medibank, nib, Bupa, HCF, CBHS, Westfund, Defence Health, TUH (not all funds at all sites) | Current | Fund schedules | Website, 2026 |
Financial Narrative
Basis.
-
FY2020 and FY2021 come from the audited Annual Report FY2021.
-
FY2017 to FY2019 revenue series come from the multi-year reconciliation in the FY2021 MD letter.
-
FY2019 EBITDA comes from the FY2021 EBITDA bridge.
-
FY2019 NPAT and EPS are derived from FY2020 NPAT of A$7.145m, reported as down about 8.1% year on year (Stockhead; Business News Australia).
-
FY2022 onwards are not publicly disclosed (private company).
-
AASB 16 (leases) applies from FY2020. FY2019 and earlier are pre-AASB 16, so EBITDA is not like-for-like.
Income statement
Sources: Annual Report FY2021 (income statement, EBITDA bridge, Notes 7 to 10); InvestSMART dividend history (FY2017 to FY2021 interim and final amounts); FNN (FY2020 dividend).
EBITDA bridge (Annual Report FY2021, AUD '000).
Note on a source conflict. Press coverage in August 2020 cited JobKeeper of about A$1.27m in FY2020 EBITDA. The audited FY2021 Annual Report shows FY2020 JobKeeper receipts of A$1.805m. The audited figure is preferred. Separately, Market Index displays FY2020 "NPAT before abnormals" of A$6.72m and "EPS with abnormals" of 28.37c, which differ from the audited A$7.145m and 30.2c. The aggregator figures are treated as unreliable.
Margins and growth
All margins are derived from the figures in 6.1.
Revenue CAGR FY2017–FY2021 (derived):
-
OTC: 6.6%
-
Statutory: 5.5%
Commentary. The five-year arc has three phases.
FY2017–FY2019: steady organic and acquisitive growth: OTC rose from A$51.0m to A$58.9m, helped by FY2019 acquisitions (Springfield Lakes, Maroochydore, Strathpine Central).
FY2020: a COVID-19 shock that the accounts partly mask: OTC fell 3.1% after practices were largely closed between 23 March and 11 May 2020. Underlying pre-AASB 16 EBITDA fell 17% to A$8.7m. Reported EBITDA rose 22%, but only because of AASB 16 (which moves rent below EBITDA), JobKeeper and one-off items. Management disclosed that revenue had been running more than 7% ahead year on year over the first three quarters, and that June 2020 was the best month in company history.
FY2021: an inflection: OTC grew 15% to a record A$65.8m. Underlying pre-AASB 16 EBITDA rose 39% to A$12.2m, and NPAT rose 35%. Same-store sales for the 26 practices operating throughout FY2019 and FY2020 were 8% (A$4m) above FY2019. During FY2019–FY2021 the company disposed of six practices and acquired six, showing active portfolio pruning.
The operating leverage is visible: dentists' share of OTC rose (A$16.4m to A$20.8m), but fixed costs (premises, support staff) grew more slowly, so incremental OTC dropped through at high rates. Second-half FY2021 moderated because of the post-lockdown catch-up in 1H and intermittent SEQ/NSW lockdowns.
Balance sheet
Source: Annual Report FY2021 (balance sheet, Notes 11, 14, 17 to 19, 24, statement of changes in equity, cash flow opening balance).
Commentary.
-
The balance sheet is goodwill-heavy. Goodwill was 71% of equity at June 2021. Net tangible assets were only 44.0c per share (including right-of-use items), which is typical of a practice roll-up.
-
Bank debt was conservative. Net leverage was 0.60x against a 2.75x covenant, and fixed-charge cover was 6.09x against a 1.80x floor.
-
The CBA facility (A$25m plus A$25m accordion, 1.89% at June 2021) was due to terminate on 2 August 2022 and was refinanced or replaced at the Abano level after the takeover.
-
A notable and unusual item is A$6.0m of redeemable preference shares in an unlisted public company, yielding 2.75% to 12% over 3 to 36 months (Note 14). The SIA separately barred any new investment in "Investors Central Limited" as a prescribed event. That suggests the counterparty, but the annual report does not name it, so this is an inference only.
-
Treasury-style investments of this kind in a dental operator were a governance and liquidity consideration flagged by the acquirer.
Cash flow
Source: Annual Report FY2021, cash flow statement.
Commentary.
-
Cash conversion was strong. FY2021 OCF of A$13.4m was 139% of NPAT and 110% of underlying pre-AASB 16 EBITDA (derived), helped by JobKeeper and low working capital needs (patients pay at the point of service).
-
Maintenance capex is light at about 3% of statutory revenue.
-
Dividends absorbed roughly 70% of post-lease FCF, with the remainder funding bolt-on acquisitions and the preference-share investments.
-
There were no buybacks or capital raisings. Shares on issue were unchanged at 23,678,384, in line with the founder's long-stated priority of protecting EPS.
Ratios
Cash conversion cycle. This is not meaningful for this model. Inventory was negligible (A$0.4m), and patients settle at the time of service (Note 2). Receivable days are shown instead.
Commentary. Returns improved sharply in FY2021: ROE 22.5% and ROIC 16.3%, against a value-in-use WACC of 8.3% (Note 19). This indicates genuine value creation above the cost of capital, which underpins the 13.5x to 15.5x EV/EBITDA takeover multiples.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
OTC revenue, non-IFRS (AUD Mn) | 51.0 | 55.8 | 58.9 | 57.1 | 65.8 |
Statutory total revenue (AUD Mn) | 36.2 | 39.3 | 42.0 | 40.699 | 44.945 |
Consumables, lab fees and supplies (AUD Mn) | — | — | — | 5.153 | 5.922 |
Gross profit, derived as revenue less consumables and lab (AUD Mn) | — | — | — | 35.546 | 39.023 |
Employee benefits expense, net of JobKeeper (AUD Mn) | — | — | — | 14.203 | 15.426 |
Reported EBITDA (AUD Mn) | — | — | 13.284 | 16.177 | 18.881 |
Underlying operating EBITDA (AUD Mn) | — | — | 10.512 | 11.652 | 15.244 |
Underlying operating EBITDA pre-AASB 16 (AUD Mn) | — | — | 10.512 | 8.746 | 12.184 |
Depreciation and amortisation (AUD Mn) | — | — | — | 5.507 | 5.236 |
Operating income, derived as PBT plus finance costs (AUD Mn) | — | — | — | 10.670 | 13.645 |
Finance costs (AUD Mn) | — | — | — | 0.884 | 0.532 |
Profit before tax (AUD Mn) | — | — | — | 9.786 | 13.113 |
Income tax expense (AUD Mn) | — | — | — | 2.641 | 3.487 |
Net profit after tax (AUD Mn) | — | — | 7.8 | 7.145 | 9.626 |
EPS basic, cents (FY2019 derived) | — | — | 32.8 | 30.2 | 40.7 |
EPS diluted, cents | — | — | — | 30.2 | 40.7 |
DPS ordinary declared for the year, cents | 23.0 | 24.0 | 25.0 | 25.75 | 14.5 |
Special DPS paid November 2021 (FY2022), cents | — | — | — | — | 100 |
Financial Analysis
| Item | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
Reported EBITDA | 13,284 | 16,177 | 18,881 |
less JobKeeper receipts | 0 | -1,805 | -2,185 |
less other one-off/non-operating revenue | -1,133 | -1,823 | -788 |
less other one-off/non-operating income | -1,639 | -897 | -664 |
Underlying operating EBITDA | 10,512 | 11,652 | 15,244 |
less rent excluded under AASB 16 | 0 | -2,906 | -3,060 |
Underlying operating EBITDA pre-AASB 16 | 10,512 | 8,746 | 12,184 |
Margin Analysis (%)
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
Statutory revenue growth % | — | 8.6 | 6.9 | -3.1 | 10.4 |
OTC revenue growth % | -0.8 | 9.4 | 5.6 | -3.1 | 15.2 |
Gross margin, derived % | — | — | — | 87.3 | 86.8 |
Underlying EBITDA margin on statutory revenue % | — | — | 25.0 | 28.6 | 33.9 |
Underlying pre-AASB 16 EBITDA margin on OTC revenue % | — | — | 17.8 | 15.3 | 18.5 |
Operating (EBIT) margin, derived % | — | — | — | 26.2 | 30.4 |
Net margin on statutory revenue % | — | — | 18.6 | 17.6 | 21.4 |
Effective tax rate % | — | — | — | 27.0 | 26.6 |
Balance Sheet
| Metric | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
Total assets (AUD Mn) | — | 74.155 | 72.770 |
Cash and equivalents (AUD Mn) | 0.634 | 6.681 | 4.247 |
Bank debt, short-term (AUD Mn) | — | 0 | 0 |
Bank debt, long-term (AUD Mn) | — | 15.000 | 13.300 |
Lease liabilities, total (AUD Mn) | — | 8.882 | 8.555 |
Net bank debt, derived (AUD Mn) | — | 8.319 | 9.053 |
Net debt incl. leases, derived (AUD Mn) | — | 17.201 | 17.608 |
Total equity (AUD Mn) | 40.085 | 41.133 | 44.366 |
Goodwill (AUD Mn) | 30.357 | 31.638 | 31.657 |
Total intangibles incl. goodwill (AUD Mn) | 33.482 | 34.308 | 33.926 |
Working capital, current assets less current liabilities (AUD Mn) | — | 0.917 | 0.633 |
Loans receivable, current plus non-current (AUD Mn) | — | 5.822 | 8.310 |
Investment property (AUD Mn) | — | 1.625 | 1.625 |
Cash Flow
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | — | 12.584 | 13.375 |
Of which JobKeeper (AUD Mn) | — | — | — | 1.805 | 2.185 |
Capex, PP&E plus intangibles (AUD Mn) | — | — | — | 1.750 | 1.295 |
Free cash flow, OCF less capex (AUD Mn) | — | — | — | 10.834 | 12.080 |
Lease principal repayments (AUD Mn) | — | — | — | 2.480 | 3.060 |
FCF after lease payments, derived (AUD Mn) | — | — | — | 8.354 | 9.020 |
Acquisitions net of cash, incl. deferred consideration (AUD Mn) | — | — | — | 1.986 | 0.885 |
Dividends paid (AUD Mn) | — | — | — | 6.097 | 6.393 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net borrowings drawn/(repaid) (AUD Mn) | — | — | — | 5.800 | -1.700 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2020 | FY2021 |
|---|---|---|
ROE on average equity, derived % | 17.6 | 22.5 |
ROA on closing assets (FY2020) / average assets (FY2021), derived % | 9.6 | 13.1 |
ROIC, NOPAT over (equity + debt + leases − cash), derived % | 13.3 | 16.3 |
Current ratio, x | 1.09 | 1.08 |
Bank debt to equity, x | 0.36 | 0.30 |
Debt incl. leases to equity, x | 0.58 | 0.49 |
Net bank debt to underlying pre-AASB 16 EBITDA, derived x | 0.95 | 0.74 |
Company-reported net leverage ratio (covenant basis), x | — | 0.60 |
Interest coverage, EBIT over finance costs, derived x | 12.1 | 25.6 |
Fixed-charge cover (covenant basis), x | — | 6.09 |
Asset turnover, derived x | 0.55 | 0.61 |
Receivable days, derived | 20 | 13 |
Payout ratio, ordinary dividends paid over NPAT % | 85.3 | 66.4 |
Region revenue
| Region revenue | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
Australia, statutory revenue (AUD Mn) | 42.0 | 40.699 | 44.945 |
Australia, growth % | 6.9 | -3.1 | 10.4 |
Rest of world (AUD Mn) | 0 | 0 | 0 |
Geographic Revenue
| Indicator | North Qld | Central Qld | South East Qld | NSW | Source |
|---|---|---|---|---|---|
Goodwill, FY2021 (AUD Mn) | 1.024 | 6.554 | 19.981 | 4.098 | Note 19 |
Goodwill change FY2020 to FY2021 (AUD Mn) | 0.015 | 0.358 | 0 | -0.354 | Note 19 |
Practice location pages, website 2026 | 7 | 7 | 11 | 1 | Website, October 2026 |
COVID-19 impact noted in 2H FY2021 | Low | Low | Intermittent lockdowns | Intermittent lockdowns | Annual Report FY2021 |
Date / Period Details
| Date / period | Share price (AUD) | Source |
|---|---|---|
May 2010 | ~2.89 (director transaction price) | InvestSMART |
August 2015 | 7.09 (post-FY2015 result) | Business News Australia |
September 2015 | ~7.00–7.08 (director buys) | InvestSMART |
April 2016 | ~6.84–6.94 | InvestSMART |
June 2017 | ~6.49 | InvestSMART |
28 June 2019 | 6.35 | Market Index |
H2 CY2019 (Maven talks) | 5.95 | FNN |
30 June 2020 | 5.16 | Market Index (financials page) |
August 2020 (FY2020 result) | 6.30 | FNN |
30 June 2021 | 6.95 | Market Index (financials page) |
20 August 2021 (undisturbed) | 7.02 | Scheme announcement |
12-month VWAP to 20 August 2021 | 6.79 | Scheme announcement |
Last trade (November 2021) | 8.13 | InvestSMART |
Valuation Multiples
| Multiple | Blended (A$7.00; EV A$165m) | Non-founder (A$8.00; EV A$188m) | Basis |
|---|---|---|---|
EV / underlying EBITDA pre-AASB 16 (x) | 13.5 | 15.5 | Company-stated, FY2021 |
P/E (x) | 17.2 | 19.7 | FY2021 EPS 40.7c, derived |
EV / statutory revenue (x) | 3.7 | 4.2 | Derived |
EV / OTC revenue (x) | 2.5 | 2.9 | Derived |
P/B (x) | 3.7 | 4.3 | FY2021 equity A$44.4m, derived |
DPS by fiscal year
| DPS by fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
Interim DPS, cents | 11.25 | 12.0 | 12.5 | 13.25 | 14.5 |
Final DPS, cents | 11.75 | 12.0 | 12.5 | 12.5 | 0 |
Total ordinary DPS, cents | 23.0 | 24.0 | 25.0 | 25.75 | 14.5 |
Analyst Conclusions
Guidance and consensus
There has been no management guidance since FY2021. The FY2021 outlook was qualitative: opportunistic acquisitions, organic growth and greenfield investigation. There is no sell-side consensus, as there was no broker coverage and the company is now private. Abano Healthcare publishes no 1300SMILES-specific targets.
Bull case
-
Proven unit economics scale inside Abano. FY2021 ROIC of 16.3% against an 8.3% WACC. Group procurement and recruitment should lift brand-level margins above the standalone 33.9% underlying EBITDA margin.
-
Regional Queensland is structurally under-served. Bolt-on acquisitions in Chinchilla and Bundaberg show a steady supply of vendor dentists seeking exits, which a well-capitalised owner can buy at accretive multiples.
-
Demand tailwinds. Ageing demographics, cosmetic and orthodontic growth, and FY2021 OTC growth of 15% with same-store sales 8% above pre-COVID indicate durable demand.
Bear case
-
Footprint contraction. About 26 listed locations in 2026 versus 33 at acquisition may signal closures or transfers into Maven, eroding the brand's standalone value.
-
Labour constraints. Dentist supply and retention risk is amplified in regional markets. Abano's 2026 international recruiting suggests persistent shortages.
-
Policy and payer risk. The CDDS precedent (−29.5% half-year revenue) and insurer network pricing can compress fees. Discounted new-patient offers (A$249) point to a price-competitive acquisition environment.
Catalysts and monitorables (next 12 months)
-
Any Abano/BGH/OTPP exit process (sale or IPO of the trans-Tasman platform) that would re-surface 1300SMILES financials.
-
Disclosure of whether the founders' retained ~16% stake was acquired by the Abano parent.
-
Changes to the CDBS or any new federal or state dental funding scheme.
-
Practice count trajectory on the 1300SMILES website (26 as of October 2026).
-
Health-fund network renegotiations.
-
Abano group leverage and refinancing activity.
Analyst verdict
1300SMILES Limited is a closed chapter as a public equity but a live operating brand. Judged on its listed record, it was one of the better-run small-cap healthcare services businesses on the ASX:
-
Statutory revenue grew from A$22.4m in FY2009 to A$44.9m in FY2021.
-
Net margins expanded above 20%.
-
The share count was held flat in the final years.
-
It paid an unbroken stream of fully franked dividends from 2005.
-
It balanced conservative leverage against selective acquisitions.
Its FY2021 result was its best, with A$65.8m OTC revenue, A$12.2m underlying pre-AASB 16 EBITDA and A$9.6m NPAT. That result was effectively the vendor's "high-water mark" sale document. The BGH/OTPP-backed Abano paid 13.5x blended (15.5x for minorities) EBITDA, a full but defensible price for a business earning a mid-teens ROIC with a long reinvestment runway in regional Queensland.
The structure was founder-friendly in an unusual way. Minorities received a 14% to 18% premium in cash. The founder accepted lower cash per share, partly contingent, and rolled about 16% of the company into the private platform. This alignment signalled confidence in the platform thesis.
The weaknesses were governance-related and are now largely moot: a small board, related-party leases, a dominant founder and an idiosyncratic treasury investment in preference shares. The open questions concern stewardship under private-equity ownership. The branded footprint appears to have shrunk to about 26 listed locations. No financial disclosure has been made since 2021, and whether the founder's retained stake was rolled into parent scrip is unknown.
Verdict. For anyone assessing exposure today, whether as a counterparty, potential acquirer of the Abano platform, landlord, or dentist, 1300SMILES should be treated as a high-quality regional asset embedded in a leveraged private platform. Its intrinsic economics are strong; its transparency is nil. Any valuation work requires primary diligence data.
Primary sources referenced
-
1300SMILES Limited Annual Report and Appendix 4E, FY2021 (ASX, 24 August 2021)
-
ASX announcement "Abano Healthcare to acquire 1300Smiles", including the Scheme Implementation Agreement dated 23 August 2021 (ASX, 24 August 2021)
-
ASX announcement "Implementation of Scheme" (1 December 2021); "Removal from Official List" (2 December 2021)
-
1300SMILES Annual Report FY2016 (ASX, 11 August 2016)
-
Company press releases and blogs (dentalcommunity.com.au; 1300smiles.com.au)
-
1300SMILES website (accessed October 2026)
-
Business News Australia; Finance News Network; Stockhead; Kalkine; AFR; NBR; Dental Tribune; DealStreetAsia
-
Aggregators used only for corroboration: InvestSMART, Market Index, MarketBeat
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior roles and education | FY2021 total remuneration (AUD) |
|---|---|---|---|---|
Robert Jones | Independent Non-Executive Chairman; IBC Chair for the Scheme | Chair from 25 September 2007 (director and chair since 2007) to 1 December 2021 | Director and Chair, Mater Health Services North Qld (1993–2013); director, Hermit Park Bus Service; MAICD | 42,160 (fees 36,864 + super 5,296) |
Dr Daryl Holmes OBE | Founder and Managing Director | Director 18 September 2000 to 1 December 2021; MD agreement from 8 March 2005 | B.D.Sc (Hons), UQ (1987); RAAF Dental Officer (1988–91); private practice from 1991; Chairman, Cowboys Leagues Club (from May 2014; director for 19 years); ADA member for 34 years; MAICD | 91,326 (salary 83,403 + super 7,923). Also earns income as a practising dentist under a DSA on commercial terms |
Jason Smith | Independent Non-Executive Director; IBC member | 23 November 2017 to 1 December 2021 | Founder and Executive Chairman, Back In Motion Health Group (100+ locations AU/NZ); author; Franchise Council of Australia member | 30,000 |
Evonne Collier | Non-Executive Director | Resigned 6 April 2020 | — | 22,500 (FY2020) |
Natalie Duve | Operations Manager (KMP) | From 18 October 2017 | — | 172,502 (salary 157,536 + super 14,966). Contract: A$168,630 package plus up to 10% STI |
Roman Chideme | Financial Controller (KMP) | From 30 September 2019 | — | 150,753. Contract: A$140,525 plus A$15,000 STI |
Patrick Wyatt | Company Secretary | Throughout FY2021 | — | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares | Stake % | Date | Source |
|---|---|---|---|---|
Dr Daryl Holmes and associated entities (TFD Hybrid Fixed Trust; Golden Arch (Qld) Pty Ltd ATF Whistler Discretionary Trust) | 14,711,729 | 62.13 | Pre-scheme | Annual Report FY2021; InvestSMART |
Ellerston Capital Limited and associates | 1,680,628 | 7.1 | August 2021 | Scheme announcement, 24 August 2021 |
Robert Jones | 37,521 | 0.16 | June 2021 | Annual Report FY2021 |
Natalie Duve | 26,692 | 0.11 | June 2021 | Annual Report FY2021 |
Jason Smith | 2,068 | 0.01 | June 2021 | Annual Report FY2021 |
Shares held under escrow (share-loan plan) | 333,324 | 1.41 | June 2021 | Note 25 |
Competitive Landscape
Key Competitors
| Competitor | Type | Scale indicator | Relative positioning vs 1300SMILES | Source |
|---|---|---|---|---|
Pacific Smiles Group (ex-ASX: PSQ) | Corporate DSO; independent-dentist centre model | FY2019 revenue A$122.2m; NPAT A$8.9m; 89 centres; FY2019 patient fees A$187.4m. Taken private in 2024 (verify) | Same service-fee model at roughly 3x scale; greenfield-led in NSW, Victoria and Queensland; lower margins | Kalkine, December 2019 |
Maven Dental Group (Abano) | Corporate DSO | 106–116 Australian practices (2019–2021) | Now a sister brand; was the largest acquisition target and a competitor for practices pre-2021 | ASX announcement, 24 August 2021; Business News Australia |
National Dental Care | Private DSO | 60+ surgeries (circa 2018); attempted IPOs 2018 and ~2021 | Direct competitor for acquisitions and dentists | AFR; Stockhead |
Smiles Inclusive (ex-ASX: SIL) | Corporate DSO | FY2019 statutory loss A$31.0m; practice revenue net of direct costs A$30.4m; debt/equity ~7x | Distressed peer; sold practices to 1300SMILES in December 2019. | Kalkine, November 2019 |
Bupa Dental | Insurer-owned clinics | — | Vertically integrated pricing advantage for Bupa members | General knowledge |
HCF Dental Centres | Insurer-owned clinics | — | Member no-gap offers; strong in NSW | General knowledge |
Medibank Members' Choice network | Insurer preferred-provider network | — | 1300SMILES is a preferred provider; network terms constrain pricing | Website |
Queensland Health Oral Health Services | Public dental | Not applicable | Free or subsidised care for eligible adults and children; competes for low-income patients | General knowledge |
Independent owner-operated practices | Fragmented | The majority of the market | Main competitors locally; also the acquisition pipeline | Annual Report FY2021 (acquisition strategy) |
SDI Limited (ASX: SDI) | Dental materials manufacturer | FY2019 sales A$79.6m | Supplier, not competitor; included for sector benchmarking | SDI FY2019 results |
“—” = not publicly disclosed.
Peer Comparison FY2021
| Metric | 1300SMILES (FY2021) | Pacific Smiles (FY2019) | Smiles Inclusive (FY2019) | Maven Dental (2021) |
|---|---|---|---|---|
Revenue (AUD Mn) | 44.9 statutory / 65.8 OTC | 122.2 | 30.4 practice revenue net of direct costs | — |
Revenue growth % | 10.4 | 16.9 | — | — |
NPAT (AUD Mn) | 9.6 | 8.9 | -31.0 | — |
Net margin % | 21.4 | 7.3 (derived) | Negative | — |
Practices | 33 | 89 | — | 106 |
R&D intensity % | 0 | 0 | 0 | 0 |
“—” = not publicly disclosed.
Recent Developments
Data limitation: * As a private subsidiary since December 2021, 1300SMILES publishes no market announcements. Part A records everything verifiable in the window.
Part A — 18-month window
| Date | Event | Significance | Source |
|---|---|---|---|
| 2025–2026 | No material corporate announcements (results, guidance, litigation, regulatory actions) identified for 1300SMILES Ltd | Consistent with private status | Web search, October 2026 |
| 2026 (ongoing) | Website lists 26 locations across 4 regions, copyright "2026 1300SMILES Ltd" | Brand retained as a distinct trading name within Abano; footprint below the 33 practices of August 2021 | Website |
| 2026 (to 15 January 2027) | New-patient check-up, clean and x-ray offer at A$249 at participating practices | Price-led patient acquisition; signals a competitive new-patient market | Website |
| 31 July 2026 | Dental Health Week 2026 campaign content published | Continuing brand marketing | Website blog |
| 2,026 | Abano Healthcare recruits clinicians internationally (e.g., British Dental Conference 2026); former 1300SMILES personnel involved | Dentist-supply constraints persist; group-level recruitment model | Public professional-network posts (low confidence) |
| 2,026 | Recruitment for 1300SMILES routed via careers.abanohealthcare.com | Shared-services integration | Website |
Part B — Extended register (final listed period)
| Date | Event | Significance | Source |
|---|---|---|---|
| 2 December 2021 | Removed from the ASX Official List | End of public disclosure | ASX |
| 1 December 2021 | Scheme implemented; final director's interest notices filed | Change of control | ASX |
| 26 November 2021 | A$1.00 fully franked special dividend paid | Distributes franking credits (A$10.8m balance at June 2021) | ASX |
| 18 November 2021 | Suspension from quotation | Scheme effective | ASX |
| 17 November 2021 | Court approval; Scheme effective | Final legal step | ASX |
| 12 November 2021 | Scheme meetings and AGM pass; dividend notice; JobKeeper payments notification | Shareholder approval | ASX |
| 13 October 2021 | Scheme Booklet registered with ASIC | Disclosure to vote | ASX |
| 31 August 2021 | Appendix 4G and Corporate Governance Statement | Compliance | ASX |
| 24 August 2021 | Consortium holding notice; MD letter; SIA announcement; FY2021 results | Deal announced; shares +15.8% to ~A$8.13 | ASX; InvestSMART |
| 23 August 2021 | Trading halt and pause in trading | Pre-deal | ASX |
| August 2021 | Fourth Bundaberg practice contracted | Growth continuation | Annual Report FY2021 |
| 1 July 2021 | Chinchilla acquisition settled | Western Downs entry | Annual Report FY2021 |
| 2H FY2021 | SEQ/NSW lockdowns affect select practices | Revenue moderation | Annual Report FY2021 |
| 1 April 2021 | Confidentiality agreement with Abano | Deal origination | SIA |
| 18 March 2021 | 14.5c interim dividend paid | Record interim | InvestSMART |
| 7 December 2020 | Bundaberg Central Point acquired | Central Queensland density | Annual Report FY2021 |
| 11 September 2020 | 12.5c final FY2020 dividend paid | Dividend continuity through COVID | Annual Report FY2021 |
| August 2020 | FY2020 results; record June revenue | Resilience | FNN |
| 21 April 2020 | Director J. Smith buys 1,997 shares at ~A$5.06 | Insider confidence at COVID trough | InvestSMART |
| April 2020 | ~50% of practices open part-time; cash conservation | COVID shock | Kalkine |
| 6 April 2020 | Director E. Collier resigns | Board shrinks to three | Annual Report FY2021 |
| February 2020 | 1H FY2020 EBITDA +31.6%; MD letter on Maven and SIL | Strategy disclosure | Business News Australia |



